CARTISTEM은 동종 제대혈 유래 중간엽 줄기세포(UCB-MSC)로, 퇴행성 무릎 관절염 환자(ICRS IV등급의 연골 결손이 있는)의 퇴행성 또는 반복적 외상으로 인한 무릎 연골 결손 치료에 사용되며, ICRS 등급은 연골 결손의 심각성을 평가하기 위한 진단 기준입니다. 입니다. IV등급은 가장 심각한 단계로, 결손 부위에 연골이 전혀 남아있지 않은 상태입니다.
메디포스트는 두 가지 전략으로 일본 시장 진출을 계획하고 있습니다. 최근 승인된 임상 3상과 별도로 경증에서 중증 무릎관절 OA(K&L등급 2-4등급) 환자 50명을 대상으로 HTO(High Tibial Osteotomy, 장경골 절골술, 장경골 인대 절골술)의 효과를 카티스템 유무에 따라 비교하는 임상 2상이 승인되었습니다, 2020년 하반기 조건부 품목허가를 목표로 진행 중입니다.
주요 6개국, 캐나다 및 한국에서 CARTISTEM 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.
목차
제1장 리포트의 서론
제2장 골관절염에 대한 CARTISTEM의 개요
- 제품 상세
- 임상 개발
- 규제상 마일스톤
- 기타 개발 활동
- 제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신규 치료법)
제5장 CARTISTEM 시장 평가
- 골관절염에 대한 CARTISTEM의 시장 전망
- 주요 6개국, 캐나다 및 한국의 분석
- 주요 6개국, 캐나다 및 한국에서 골관절염에 대한 CARTISTEM의 시장 규모
- 국가별 시장 분석
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
“"CARTISTEM Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CARTISTEM for osteoarthritis in the six major markets. A detailed picture of the CARTISTEM for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the CARTISTEM for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CARTISTEM market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.
Drug Summary:
CARTISTEM is an allogeneic umbilical cord blood-derived mesenchymal stem cells (UCB-MSC) used to treat knee cartilage defects in patients with OA (with ICRS grade IV cartilage defect) caused by degeneration or repetitive trauma. ICRS grade is a diagnostic criterion used for grading the severity of cartilage defects. Grade IV is the most severe stage, with no visible cartilage remaining on the defect area.
Medipost is also planning to enter the Japanese market with a two-track strategy. Separately from the recently approved Phase III clinical trial and a Phase II clinical trial to compare the effects of HTO (High Tibial Osteotomy, a procedure to treat bowlegs [genu varum]) with/without CARTISTEM in 50 patients with mild to severe knee OA (K&L Grade 2-4) is ongoing to obtain conditional product approval since the second half of 2020.
Scope of the Report:
The report provides insights into:
- A comprehensive product overview including the CARTISTEM description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
- Elaborated details on CARTISTEM regulatory milestones and other development activities have been provided in this report.
- The report also highlights the CARTISTEM research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
- The report also covers the patents information with expiry timeline around CARTISTEM.
- The report contains forecasted sales of CARTISTEM for osteoarthritis till 2032.
- Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
- The report also features the SWOT analysis with analyst views for CARTISTEM in osteoarthritis.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
CARTISTEM Analytical Perspective by DelveInsight
- In-depth CARTISTEM Market Assessment
This report provides a detailed market assessment of CARTISTEM for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.
- CARTISTEM Clinical Assessment
The report provides the clinical trials information of CARTISTEM for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
- In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CARTISTEM dominance.
- Other emerging products for osteoarthritis are expected to give tough market competition to CARTISTEM and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CARTISTEM in osteoarthritis.
- Our in-depth analysis of the forecasted sales data of CARTISTEM from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CARTISTEM in osteoarthritis.
Key Questions
- What is the product type, route of administration and mechanism of action of CARTISTEM?
- What is the clinical trial status of the study related to CARTISTEM in osteoarthritis and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CARTISTEM development?
- What are the key designations that have been granted to CARTISTEM for osteoarthritis?
- What is the forecasted market scenario of CARTISTEM for osteoarthritis?
- What are the forecasted sales of CARTISTEM in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
- What are the other emerging products available and how are these giving competition to CARTISTEM for osteoarthritis?
- Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?
Table of Contents
1. Report Introduction
2. CARTISTEM Overview in Osteoarthritis
- 2.1. Product Detail
- 2.2. Clinical Development
- 2.2.1. Clinical studies
- 2.2.2. Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Regulatory Milestones
- 2.4. Other Developmental Activities
- 2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. CARTISTEM Market Assessment
- 5.1. Market Outlook of CARTISTEM in Osteoarthritis
- 5.2. 6MM, Canada and Korea Analysis
- 5.2.1. Market Size of CARTISTEM in the 6MM, Canada and Korea for Osteoarthritis
- 5.3. Country-wise Market Analysis
- 5.3.1. Market Size of CARTISTEM in the United States for Osteoarthritis
- 5.3.2. Market Size of CARTISTEM in Germany for Osteoarthritis
- 5.3.3. Market Size of CARTISTEM in France for Osteoarthritis
- 5.3.4. Market Size of CARTISTEM in Italy for Osteoarthritis
- 5.3.5. Market Size of CARTISTEM in Spain for Osteoarthritis
- 5.3.6. Market Size of CARTISTEM in the United Kingdom for Osteoarthritis
- 5.3.7. Market Size of CARTISTEM in Canada for Osteoarthritis
- 5.3.8. Market Size of CARTISTEM in Korea for Osteoarthritis
6. SWOT Analysis
7. Analysts' Views
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
12. Report Purchase Options
